| Name | Title | Contact Details |
|---|
Establishment Labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. With more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for Establishment Labs` founders and top executives. As a result, Motiva Implants® has established a level of product innovation that always results in safety. And while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. We believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.
The Anspach Effort, Inc. is a successful, continuously evolving business whose focus concentrates on high-speed instrumentation for Neurosurgery, Neurotology, Otology, and Orthopedics. The company is committed to providing product quality, technology,
Mainstay is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
Clinicon Corporation is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.